SesaVita-Supports Healthy Blood Sugar and Cholesterol Levels

07 May 2014
15:20 - 15:45
Chair person  Robert Thomas
Speaker(s)  Shivaprasad Hebbani Nagarajappa

Co-Authored by: M. Bhanumathy, Olive Lifesciences Pvt. Ltd; Ceyhun Tamer, BioActives Europe GmbH; G. Sushma, Olive Lifesciences Pvt. Ltd; K.R. Raveendra, Bangalore Medical College & Research Institute; K. Venkateshwarlu, Srinivasa Clinic & Diabetic Care Centre.


Prediabetes, also known as intermediate hyperglycemia, is a high-risk state for diabetes. It is defined as glycemic variables that are higher than normal, but lower than the diabetes threshold. Prediabetic subjects have distinctive forms of dyslipidemia characterized by low high-density lipoprotein cholesterol (HDL-C) levels and modestly elevated levels of triglyceride-rich lipoproteins. There may or may not be elevations of low-density lipoprotein cholesterol (LDL-C) levels, although commonly there is a dysmetabolism of triglyceride-rich lipoproteins leading to an overabundance of smaller, denser LDL particles. As a natural remedy - SesaVitaTM, an herbal food supplement containing Sesame seeds (Sesamum indicum L.) extract can be used in the management of healthy lipid profile and blood glucose levels.

In a 6-week, randomized, double-blind, placebo-controlled experimental trial the efficacy and safety of SesaVitaTM as a dietary supplement was evaluated for lowering lipids and blood sugar levels. Twenty subjects of prediabetes and mild to moderate hyperlipidemia were randomized to receive SesaVitaTM or placebo along with therapeutic lifestyle changes (TLC) including low fat diet, weight management and increased physical activity for 6 weeks. SesaVitaTM (n = 11) or placebo (n = 9) was administered orally twice a day (500 mg/day in divided doses), 20 minutes before breakfast and dinner. The primary outcome was the measure of efficacy in terms of change in serum lipid profile and glycaemic levels on week 3 and 6. Secondary outcome measures include safety and tolerability evaluated by physical examination and clinical laboratory evaluations.

The high performance liquid chromatography (HPLC) characterization of SesaVitaTM revealed the presence of 71.11% w/w total sesamin complex. Thus the lowering plasma cholesterol and glycaemic levels might be related to the amounts of sesamin from sesame seeds. The findings from this investigation has provided valuable information on the probable efficacy and safety of SesaVitaTM in managing prediabetes and mild to moderate hyperlipidemia by lowering serum cholesterol and glycaemic levels.

Who Should Attend and why:

  • R & D Scientists, Vice President-Technical and the Nutraceutical formulators
  • By attending this they get complete research and clinical study on ingredients which can be positioned for cholesterol management and blood sugar lowering property.
  • By the year 2030, more than 470 million people will have prediabetes in worldwide. Prediabetes people may suffer from the factors such as hyperlipidemia, hypertension and insulin resistance-linked obesity which increase the risk of heart disease. Nutraceutical supplements may help in the management of healthy blood sugar and cholesterol levels.
Media Partners
Online media partner
Online media partner
What do you think?
Can better nutrition ever achieve its promise to reduce chronic disease and public health care costs?
Yes - but better clarity is needed on food labelling and marketing regulation
Only if legislation banning certain foods is introduced
No - you can't force people to change lifestyle patterns
No - food manufacturers are more concerned with profit than public health
See ingredients come to life at our co-located dietary supplements event
See the full supply chain at Finished Products Europe
The Vitafoods Events worldwide:
Vitafoods Asia Vitafoods Africa Vitafoods South Africa   Finished Products Europe